Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045922 | 0.87 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7989269 | 0.87 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL11356824 | 0.87 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7989530 | 0.87 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL1046331 | 0.83 | ALDH1A1 (0.70) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL11852 | 0.83 | HRH3 (0.74) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL13215736 | 0.83 | ALDH1A1 (0.70) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL979535 | 0.81 | ALDH1A1 (0.67) | ALDH1A1POLBMEN1KMT2AHRH3 | |
| SCHEMBL1045984 | 0.81 | ALDH1A1 (0.74) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL1045595 | 0.81 | ALDH1A1 (0.74) | ALDH1A1LMNAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | claimed |
| EP-1753749-B1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | claimed |
| CN-1980917-B | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV | 2014-02-12 | — | — | CN | claimed |
| US-7282507-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | claimed |
| CN-1980917-A | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | claimed |
| EP-1753749-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-21 | — | — | EP | claimed |
| WO-2005111028-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | claimed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | claimed |
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| CN-105061422-B | Pyrazolo pyridine derivatives and application thereof | 吉恩基奥泰克斯瑞士股份有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-9434688-B2 | Indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| CN-105061422-A | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX S A | 2015-11-18 | — | — | CN | disclosed |
| CN-101686967-B | Pyrazolopyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX S.A. (CH) | 2015-08-19 | — | — | CN | disclosed |
| EP-2078712-B1 | Indole derivatives as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-10 | — | — | EP | disclosed |
| WO-2005110985-A2 | INDOLE, BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111042-A1 | NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-03 | — | — | US | disclosed |
| EP-0280873-A1 | Piperidines, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250741-A1 | non-steroidal agonists and antagonists; 2-(2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5--carbonitrile; anticarcinogenic; prostate carcinoma, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive | AR, NR5A1, FSHR | ALDH1A1 1696/4885LMNA 2491/4885POLB 3674/4885 |
| US-20050245485-A1 | Novel indole derivatives as selective androgen receptor modulators (SARMS) | AR, NR5A1, NR5A2 | ALDH1A1 1333/4885LMNA 4411/4885POLB 4300/4885 |
| US-20050250740-A1 | Novel indole derivatives as selective androgen receptor modulator (SARMS) | AR, NR5A1, NR5A2 | ALDH1A1 1274/4885LMNA 4431/4885POLB 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.